Skip to main content Skip to navigation
Purified Mouse Anti-DSIF
Product Details
Down Arrow Up Arrow


BD Transduction Laboratories™
Human (QC Testing), Mouse,Rat,Dog (Tested in Development)
Mouse IgG1
Human DSIF aa. 866-985
Western blot (Routinely Tested), Immunofluorescence (Tested During Development)
160 kDa
250 µg/ml
AB_398420
Aqueous buffered solution containing BSA, glycerol, and ≤0.09% sodium azide.
RUO


Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at -20°C.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
611107 Rev. 1
Antibody Details
Down Arrow Up Arrow
17/DSIF

In living systems, the relative amounts of any protein are controlled at many levels. For example, amounts are affected by protein degradation, regulation of the translational rates of polypeptide synthesis (translational regulation), and control of the rates of mRNA synthesis (transcriptional regulation). Transcriptional regulation involves modulation of the rate-limiting enzyme RNA polymerase. DSIF (DRB sensitivity-inducing factor) is a heterodimeric transcription elongation protein. It is composed of a large subunit of 160 kDa and a small subunit of 14 kDa. These large and the small subunits are homologs of the yeast gene products Stp5 and Stp4, respectively. Spt4 and 5 are transcription factors which are critically important for the activity of RNA polymerase. In conjunction with DRB, DSIF attenuates RNA polymerase II elongation steps. However, in limiting amounts of ribonucleotides, DSIF, by itself, stimulates the elongation rate of RNA polymerase II. Thus, the identification of a human regulator for transcriptional elongation will greatly enhance our understanding of this critical step in mammalian gene expression.

This antibody is routinely tested by western blot analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.

611107 Rev. 1
Format Details
Down Arrow Up Arrow
Purified
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
Purified
611107 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "611107" on CiteAb

Development References (1)

  1. Kim YK, Bourgeois CF, Isel C, Churcher MJ, Karn J. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol. 2002; 22(13):4622-4637. (Biology: Western blot). View Reference
611107 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.

Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.